Paul Hopper understands the retail IMU shareholders very well.
DTIL didn't do this deal because they wanted to, but because like most small to medium biotechs, they are finding it very hard to impossible to raise capital. Like a sinking balloon, many biotechs are having to throw out of the basket anything they can to try and stay afloat.
Ann: Theranostic prostate cancer trial advances to cohort 3, page-66
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.67 |
Change
-1.060(12.1%) |
Mkt cap ! $2.451B | |||
| Open | High | Low | Value | Volume |
| $8.62 | $8.68 | $7.67 | $13.44M | 1.664M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21192 | $7.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.72 | 59 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |